DV
Dividend Vision

KYTX — Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics, Inc. Common Stock (KYTX)

Total return is -72.8% over the past 2.5 years, 133.3 points behind SPY at 60.5%. Its deepest 1-year drawdown was 37.2%.

Kyverna Therapeutics is a late-stage biopharmaceutical company developing cell therapies for autoimmune diseases, with its lead product candidate KYV-101, an autologous CD19 CAR T-cell therapy in development for stiff person syndrome, myasthenia gravis, and other autoimmune conditions. The company does not currently distribute dividends. This security appeals to investors seeking exposure to clinical-stage biopharmaceutical development with a focus on cell therapy innovation.

KYTX key facts

Asset type
Stock
Asset class
Equity
Inception date
02/08/2024
Last close
$8.17
Market cap
$440,157,312
Average volume
580000.0
Beta
1.877
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.17